# A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

> **NCT02927340** · PHASE2 · UNKNOWN · sponsor: **Massachusetts General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT02927340
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2022-01
- **Final completion:** 2023-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02927340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02927340, "A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02927340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*